J&J Resolves 5 Risperdal Off-Label Marketing Cases

Law360, Philadelphia (October 4, 2012, 5:45 PM EDT) -- Johnson & Johnson agreed Thursday to settle five cases it was facing in Pennsylvania state court alleging the antipsychotic drug Risperdal was illegally marketed to children and caused abnormal breast growth in young boys.

The terms of the settlements, which were announced as jury selection in one of the cases was set to begin in the Philadelphia Court of Common Pleas on Thursday, were not disclosed, but attorneys for the plaintiffs said their clients were pleased.

“The clients are satisfied and that's our job — to...
To view the full article, register now.